Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy

Monopar Therapeutics Inc. (NASDAQ:MNPR) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, Chardan analyst Keay Nakae began coverage of the company’s stock with a “Buy” rating and a price objective of $60, as reported by The Fly. The firm cited potential in its late-stage Wilson disease treatment as well as an early-stage radiopharmaceutical pipeline for the rating.  In the research note, the analyst mentioned that the company’s co-founder and Chief Executive Officer has a long history with the development of ALXN1840.

Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy

Close-up of a scientist using a microscope to study a sample, as part of a research project related to cancer prevention.

On May 7, 2025, Monopar Therapeutics Inc. (NASDAQ:MNPR) presented long-term efficacy and safety data for ALXN1840 (tiomolybdate choline). The data supported ALXN1840 as a potential treatment for Wilson disease. Pooled results from 3 clinical trials (n=255) exhibited sustained clinical benefits over a median treatment duration of 2.63 years. Monopar Therapeutics Inc. (NASDAQ:MNPR), in collaboration with Excel Diagnostics and Nuclear Oncology Center (EDNOC), announced that the physician-sponsored Expanded Access Program (EAP) for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu has received authorization to proceed from the US FDA.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None.